"The work conducted within the project has moved along three main axes geared to address the project’s threefold objective, namely (i) the charting of European framings and imaginaries of translation, (ii) the analysis of the sociotechnical dynamics underpinning regulatory and policy initiatives geared to accelerate biomedical innovation, and (iii) the assessment of the socio–political import of translational initiatives in the political macro–area of the EU.
First, drawing from the tools of discursive and argumentative policy analysis, I conducted a thorough charting of EU policy and regulatory documents to identify distinct framings of translation, and how they relate to those advanced by specific actor groups and domestic governmental agencies. This work has resulted in a co-authored and forthcoming article comparing framings and imaginaries of translation in the EU and the US (Aarden, Marelli and Blasimme, in review for Science, Technology & Human Values).
Second, I focused at length on scrutinizing regulatory (e.g. Regulation (EU) 2016/679 on data protection, Regulation (EU) 536/2014 on clinical trials) and policy initiatives geared to accelerate biomedical innovation in the continent, with the aim to identify and critically assess the governance challenges and the social, political, and ethical implications of such undertakings. This work – conducted through an interdisciplinary perspective rooted in STS and cognate disciplines – has resulted in a number of published and forthcoming studies, which identified and aimed to shed light on the challenges faced by current governance and regulatory approaches and their relevant implications in the following domains:
(i) digital health (Marelli et al. 2020; Sanchini and Marelli 2019);
(ii) genomics (Shabani and Marelli 2019; Shabani, Dyke, Marelli and Borry 2018);
(iii) translational research (De Miguel, Marelli et al. 2020; Marelli, Testa and Van Hoyweghen in submission);
(iv) biobanking (Shabani, Chassang and Marelli 2021);
In addition, I analyzed the broader political import of the efforts to advance data-intensive (biomedical) innovation for the European Union within an edited volume with contribution from world-leading STS, science policy, data governance and legal scholars (Marelli, Dratwa, Verschraegen, Van Hoyweghen, in preparation).
Finally, I was able to bring the insights gathered during the course of the project to bear on a number of high-level policy initiatives:
(i) In August 2018 I was appointed as Scientific Secretary of the ACC-GDPR Committee (comprising 25 leading experts from multidisciplinary backgrounds) set up under the aegis of the Italian Ministry of Health and the Executive Committee of Alliance Against Cancer (the leading oncologic research network in Italy) to devise ministerial guidelines for the implementation of national and EU legislation of data protection for the health research activities of the 51 leading Italian research hospitals.
(ii) In July 2019, I was appointed as Member of the Scientific Committee within the Research Ethics and Bioethics Committee, Italian National Research Council (CNR).
(iii) In April 2020, I took part as country expert for Italy in an initiative put in place by the EU Commission (DG SANTE and CHAFEA) to comprehensively chart the legal and governance landscape around health data processing across EU Member States, so as to identify challenges and affordances for the development of a European Health Data Space.
All these initiatives represented a prominent way to disseminate and ""translate"" the scholarly findings of the project into tangible policy outcomes."